NCT03497845 - Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 | Biotech Hunter

Enrollment

720

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions

Influenza A Virus, H5N1 Subtype

Interventions

BIOLOGICAL

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

dk/BANG

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

gf/WA

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

bhg/QL

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

AS03 adjuvant

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

BIOLOGICAL

MF59 adjuvant

0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose

Trial Locations (6)

14609

Rochester Clinical Research, Inc, Rochester

20850

Optimal Research, Rockville

40509

Central Kentucky Research Associates Inc, Lexington

61614

Optimal Research, Peoria

66219

Johnson County Clin-Trials, Lenexa

92108

Optimal Research, San Diego

All Listed Sponsors

lead

Biomedical Advanced Research and Development Authority

FED